{"created":"2023-06-19T10:37:43.555011+00:00","id":1833,"links":{},"metadata":{"_buckets":{"deposit":"8f3c7d2c-2ddb-4ff7-aa17-1ca36b80dc66"},"_deposit":{"created_by":16,"id":"1833","owners":[16],"pid":{"revision_id":0,"type":"depid","value":"1833"},"status":"published"},"_oai":{"id":"oai:iwate-pu.repo.nii.ac.jp:00001833","sets":[]},"author_link":["3481","3482","3483","3484","3485"],"item_7_biblio_info_12":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-01-01","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"66","bibliographicPageStart":"57","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"岩手県立大学看護学部紀要","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of the Faculty of Nursing, Iwate Prefectural University","bibliographic_titleLang":"en"}]}]},"item_7_description_10":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"症例1。43歳女性。peginterferon-α 2A および ribavirin の併用療法を行った。治療開始前甲状腺機能は正常で、TgAb,TPOAb は弱陽性であった。治療開始20週後、甲状腺機能低下を示し、治療を中止した。治療中止4週後には、TSH 142.7μIU/mL、FT3 0.8pg/mL、FT4 0.3ng/dLまで悪化した。自他覚症状、甲状腺腫も無かったので、無処置で経過観察を行ったところ、治療中止22週後甲状腺機能は正常化した。無痛性甲状腺炎の自然経過と考えられた。経過中TRAb,TSAb,TSBAbは陰性であった。 症例2。45歳男性。2009年7月24日、Peginterferon-α 2a の投与を開始。治療開始28週後、甲状腺機能低下を示し治療を中止した。治療中止8週後には、TSH 207.1μIU/mL、FT3 1.3pg/mL 、FT4 0.2ng/dLまで悪化し、ThyradinS100μg/day の投与を開始した。その後検査値は漸次改善し、治療中止17週後にはほぼ正常化した。経過中TSBAb,は陰性であった。潜在性甲状腺機能障害に無痛性甲状腺炎を合併した症例と考えられた。両例ともTSBAbが陰性で、自他覚症状の欠如との関連が示唆された。","subitem_description_type":"Other"}]},"item_7_description_11":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"Patient 1 was a 43-year-old woman on combined treatment with peginterferon-α 2a and ribavirin. Before starting treatment, TgAb and TPOAb were slightly positive. At 20 weeks after starting treatment, hypothyroidism developed, and treatment was discontinued. At 4 weeks after treatment discontinuation, TSH had worsened to 142.7 μIU/mL, FT3 to 0.8 pg/mL, and FT4 to 0.3 ng/dL. The patient had no overt clinical manifestations, and was thus followed up without specific therapy. At 22 weeks after treatment discontinuation, her thyroid function normalized. This was regarded as the natural course for painless thyroiditis. During the clinical course, TRAb, TSAb and TSBAb were negative. Patient 2 was a 45-year-old man who was started on peginterferon-α 2a, followed 3 weeks later with combined ribavirin. Before onset, TgAb, TPOAb and TRAb were positive. At 28 weeks after starting treatment, hypothyroidism developed, and treatment was discontinued. At 8 weeks after treatment discontinuation, TSH had worsened to 207.1 μIU/mL, FT3 to 1.3 pg/mL, and FT4 to 0.2 ng/dL. Although the patient had no overt clinical manifestations, Thyradin S 100μg/day was started. Subsequently, laboratory values improved gradually, and by 17 weeks after treatment discontinuation, they had normalized. During the clinical course, TSBAb was negative. This case was regarded as a combination of latent hypothyroidism and painless thyroiditis. In both cases, TSBAb was not detected, thus suggesting a relationship with the absence of overt clinical manifestations.","subitem_description_type":"Other"}]},"item_7_description_15":{"attribute_name":"表示順","attribute_value_mlt":[{"subitem_description":"9","subitem_description_type":"Other"}]},"item_7_description_16":{"attribute_name":"アクセション番号","attribute_value_mlt":[{"subitem_description":"KJ00008027319","subitem_description_type":"Other"}]},"item_7_description_8":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"症例報告","subitem_description_type":"Other"}]},"item_7_source_id_1":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AA11373559","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"13449745","subitem_source_identifier_type":"PISSN"}]},"item_7_text_7":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Faculty of Nursing, Iwate Prefectural University"},{"subitem_text_language":"en","subitem_text_value":"Faculty of Nursing, Iwate Prefectural University"},{"subitem_text_language":"en","subitem_text_value":"Iwate Seiwa Hospital"},{"subitem_text_language":"en","subitem_text_value":"Health Administration Center, Iwate Medical University"},{"subitem_text_language":"en","subitem_text_value":"Chugai Pharmaceutical Company "}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ishikawa, Kazuyoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3481","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nitatori, Tohru","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3482","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakakarumai, Chihoko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3483","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Isobe, Naoko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3484","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tamoto, Akira","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3485","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-12-27"}],"displaytype":"detail","filename":"KJ00008027319.pdf","filesize":[{"value":"4.2 MB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"KJ00008027319.pdf","objectType":"fulltext","url":"https://iwate-pu.repo.nii.ac.jp/record/1833/files/KJ00008027319.pdf"},"version_id":"a780c0a5-a345-451a-8d0d-821740133659"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ペグインターフェロン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"甲状腺機能低下症","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"無痛性甲状腺炎","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"潜在性甲状腺障害","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"甲状腺自己抗体","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"peginterferon","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"hypothyroidism","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"painless thyroiditis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"latent thyroid dysfunction","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"thyroid autoantibody","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Two patients with chronic hepatitis C who displayed a hypothyroidism during peginterferon therapy without clinical manifestations : Significance of negativity for thyroid-stimulation blocking antibody","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Two patients with chronic hepatitis C who displayed a hypothyroidism during peginterferon therapy without clinical manifestations : Significance of negativity for thyroid-stimulation blocking antibody","subitem_title_language":"en"}]},"item_type_id":"7","owner":"16","path":["274"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2016-12-27"},"publish_date":"2016-12-27","publish_status":"0","recid":"1833","relation_version_is_last":true,"title":["Two patients with chronic hepatitis C who displayed a hypothyroidism during peginterferon therapy without clinical manifestations : Significance of negativity for thyroid-stimulation blocking antibody"],"weko_creator_id":"16","weko_shared_id":-1},"updated":"2024-06-21T00:55:54.256227+00:00"}